As major pharmaceutical companies continue to battle for dominance in the high-stakes market for metabolic health, strategic corporate maneuvers remain top of mind for industry observers. Novo Nordisk, which generates the vast majority of its revenue from specialized diabetes and obesity products, faces intensifying competition from rival drugmakers launching new therapeutics. Amid this shifting competitive landscape, Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy features prominently in market discussions regarding how the Danish pharmaceutical giant might reinforce its product pipeline.
What Changed in the Obesity Treatment Landscape
Novo Nordisk has actively pursued external assets to maintain its competitive edge in the metabolic sector. The company recently completed an acquisition of three obesity assets from privately held biotech firm Kallyope. This deal underscores a broader corporate willingness to look outside its internal laboratories to secure promising drug candidates.
At the same time, the wider weight-loss treatment sector has seen dramatic capital raises and public market debuts. Notably, Kailera Therapeutics went public earlier this year in what stood at the time as the largest biotechnology initial public offering in history. Kailera established its foundational pipeline by licensing a robust portfolio of weight-loss candidates from a China-based company.
Key Pipeline Assets at Kailera Therapeutics
Kailera’s portfolio features several advanced compounds targeting critical metabolic pathways. Among them is ribupatide, a GLP-1 and GIP hormone mimic available in both subcutaneous and oral formulations. The company’s subcutaneous ribupatide candidate is currently undergoing a Phase 3 clinical study in weight loss, with data expected to arrive in 2028.
Beyond ribupatide, Kailera’s development pipeline includes KAI-7535, an investigational oral weight-loss medicine currently evaluated in a global Phase 2 obesity study. The company is also advancing KAI-4729, which mimics three distinct hormone pathways: GLP-1, GIP, and glucagon. Market analysts note that KAI-4729 could potentially produce substantial weight loss, behaving similarly to Eli Lilly’s triple agonist retatrutide, though industry experts caution that Eli Lilly’s success does not automatically guarantee that KAI-4729 will follow the exact same path.
Viking Therapeutics as a Complementary Target
Another prominent contender frequently cited by analysts is Viking Therapeutics. Viking has made significant clinical headway with its subcutaneous candidate VK2735. The drug recently posted encouraging results from a maintenance study in which patients lost 16% to 19% of their weight over a five-month period. Furthermore, patients maintained weight better using monthly or every-other-week dosing compared to a placebo group over a 12-week period.
In addition to the ongoing Phase 3 clinical trials for subcutaneous VK2735, Viking is preparing an upcoming oral formulation of the compound. The company is also advancing Phase 1 studies for VK3019, an investigational asset that mimics amylin and calcitonin. From a technical standpoint, combining VK2735 with VK3019 could theoretically target four distinct hormone pathways simultaneously, offering a compelling scientific rationale for a larger pharmaceutical buyer.
Business Implications and Novo's Internal Pipeline
While external acquisitions offer a rapid route to expansion, Novo Nordisk is simultaneously advancing its own proprietary assets. The company’s internal pipeline includes advanced Phase 3 assets such as zenagamtide and the triple agonist UBT251.
However, the commercial stakes are exceptionally high as competitors like Eli Lilly roll out new products. Acquiring a specialized player like Kailera Therapeutics or Viking Therapeutics would instantly broaden Novo’s therapeutic breadth. Alternatively, market observers suggest that Novo Nordisk might choose to diversify its lineup and pipeline entirely by acquiring a company with a completely different scientific specialization.
Risks, Limitations, and Uncertainties
Despite the clear strategic appeal of these potential transactions, several limitations and uncertainties remain. Regulatory timelines and clinical trial outcomes are inherently unpredictable. For instance, data for Kailera’s subcutaneous ribupatide Phase 3 study is not projected to arrive until 2028, leaving a substantial window for clinical adjustments.
Moreover, it remains entirely uncertain whether Novo Nordisk will ultimately choose to acquire Kailera Therapeutics, Viking Therapeutics, or another organization altogether. Corporate strategy shifts, valuation mismatches, and antitrust considerations could influence executive decisions. Whether Novo opts for metabolic consolidation or broader scientific diversification will depend heavily on upcoming clinical readouts and competitive pressures.
What to Watch Next
Industry stakeholders will monitor upcoming clinical trial readouts from both Kailera and Viking for definitive efficacy and safety signals. Key milestones to watch include the progression of Viking’s oral formulation of VK2735, early Phase 1 data for VK3019, and the global Phase 2 obesity study results for Kailera’s KAI-7535. These developments will likely dictate whether acquisition talks materialize into formal corporate transactions.